Petrus J W Naudé1, Alain D Dekker2, Antonia M W Coppus3, Yannick Vermeiren4, Ulrich L M Eisel5, Cornelia M van Duijn6, Debby Van Dam4, Peter P De Deyn2. 1. Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Department of Molecular Neurobiology, University of Groningen, Groningen, The Netherlands. 2. Department of Neurology and Alzheimer Research Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium. 3. Dichterbij, Center for the Intellectually Disabled, Gennep, The Netherlands Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands Department of Primary and Community Care (152 ELG), Radboud University Medical Center, Nijmegen, The Netherlands. 4. Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Wilrijk, Antwerp, Belgium. 5. Department of Molecular Neurobiology, University of Groningen, Groningen, The Netherlands University Center of Psychiatry & Interdisciplinary Center of Psychopathology of Emotion regulation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 6. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract
BACKGROUND: The majority of people with Down syndrome (DS) develop dementia due to Alzheimer's disease (AD). Neuropathological features are characterized by an accumulation of amyloid-β (Aβ) deposits and the presence of an activated immune response. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a newly identified (neuro)inflammatory constituent in AD. OBJECTIVE: This study examines NGAL as an inflammatory marker in DS and its associations with plasma Aβ peptides according to the follow-up clinical diagnosis of dementia. METHODS: Baseline serum NGAL and plasma Aβ40, Aβ42, Aβ(n40), and Aβ(n42) were quantified in 204 people with DS. The diagnosis of dementia in DS was established by follow-up clinical assessments. The following study groups were characterized: DS with AD at baseline (n = 67), DS without AD (n = 53), and non-demented DS individuals that converted to AD (n = 84). Serum NGAL was analyzed in 55 elderly non-DS, non-demented people. RESULTS: Serum NGAL levels were significantly increased in DS subjects compared to non-DS people. Serum NGAL levels were not associated with clinical dementia symptoms in DS. However, NGAL was positively associated with Aβ42 and Aβ(n42) in demented DS individuals and with Aβ40 and Aβ(n40) in the non-demented DS group. NGAL was negatively associated with Aβ42/Aβ40 and Aβ(n42)/Aβ(n40) ratios in converted DS subjects. These associations persisted for Aβ(n40), Aβ42/Aβ40, and Aβ(n42)/Aβ(n40) after adjusting for demographics measures, apolipoprotein E ε4 allele, platelets, and anti-inflammatory medication. CONCLUSION: Serum NGAL levels are increased in DS and associated with distinct species of Aβ depending on the progression of dementia as diagnosed by baseline and follow-up clinical assessments.
BACKGROUND: The majority of people with Down syndrome (DS) develop dementia due to Alzheimer's disease (AD). Neuropathological features are characterized by an accumulation of amyloid-β (Aβ) deposits and the presence of an activated immune response. Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a newly identified (neuro)inflammatory constituent in AD. OBJECTIVE: This study examines NGAL as an inflammatory marker in DS and its associations with plasma Aβ peptides according to the follow-up clinical diagnosis of dementia. METHODS: Baseline serum NGAL and plasma Aβ40, Aβ42, Aβ(n40), and Aβ(n42) were quantified in 204 people with DS. The diagnosis of dementia in DS was established by follow-up clinical assessments. The following study groups were characterized: DS with AD at baseline (n = 67), DS without AD (n = 53), and non-demented DS individuals that converted to AD (n = 84). Serum NGAL was analyzed in 55 elderly non-DS, non-demented people. RESULTS: Serum NGAL levels were significantly increased in DS subjects compared to non-DS people. Serum NGAL levels were not associated with clinical dementia symptoms in DS. However, NGAL was positively associated with Aβ42 and Aβ(n42) in demented DS individuals and with Aβ40 and Aβ(n40) in the non-demented DS group. NGAL was negatively associated with Aβ42/Aβ40 and Aβ(n42)/Aβ(n40) ratios in converted DS subjects. These associations persisted for Aβ(n40), Aβ42/Aβ40, and Aβ(n42)/Aβ(n40) after adjusting for demographics measures, apolipoprotein E ε4 allele, platelets, and anti-inflammatory medication. CONCLUSION: Serum NGAL levels are increased in DS and associated with distinct species of Aβ depending on the progression of dementia as diagnosed by baseline and follow-up clinical assessments.
Authors: Carolyn N Mann; Shamulailatpam Shreedarshanee Devi; Corey T Kersting; Amber V Bleem; Celeste M Karch; David M Holtzman; Gilbert Gallardo Journal: Sci Transl Med Date: 2022-02-16 Impact factor: 19.319
Authors: Maria Florencia Iulita; Diana Garzón Chavez; Maria Klitgaard Christensen; Natalia Valle Tamayo; Oleguer Plana-Ripoll; Sonja A Rasmussen; Marta Roqué Figuls; Daniel Alcolea; Laura Videla; Isabel Barroeta; Bessy Benejam; Miren Altuna; Concepción Padilla; Jordi Pegueroles; Susana Fernandez; Olivia Belbin; María Carmona-Iragui; Rafael Blesa; Alberto Lleó; Alexandre Bejanin; Juan Fortea Journal: JAMA Netw Open Date: 2022-05-02
Authors: Lori N Eidson; George T Kannarkat; Christopher J Barnum; Jianjun Chang; Jaegwon Chung; Chelsea Caspell-Garcia; Peggy Taylor; Brit Mollenhauer; Michael G Schlossmacher; Larry Ereshefsky; Mark Yen; Catherine Kopil; Mark Frasier; Kenneth Marek; Vicki S Hertzberg; Malú G Tansey Journal: J Neuroinflammation Date: 2017-08-18 Impact factor: 8.322
Authors: André Strydom; Antonia Coppus; Rafael Blesa; Adrian Danek; Juan Fortea; John Hardy; Johannes Levin; Georg Nuebling; Anne-Sophie Rebillat; Craig Ritchie; Cornelia van Duijn; Shahid Zaman; Henrik Zetterberg Journal: Alzheimers Dement (N Y) Date: 2018-12-13
Authors: Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom Journal: Nat Rev Neurosci Date: 2015-08-05 Impact factor: 34.870
Authors: Debby Van Dam; Yannick Vermeiren; Alain D Dekker; Petrus J W Naudé; Peter P De Deyn Journal: Curr Alzheimer Res Date: 2016 Impact factor: 3.498
Authors: Alessandra C Martini; Alex M Helman; Katie L McCarty; Ira T Lott; Eric Doran; Frederick A Schmitt; Elizabeth Head Journal: Alzheimers Dement (Amst) Date: 2020-10-14